ArticleTranslational lung cancer research2019
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Article in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.Chinese medical journal · 2026Trial
- Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.Scientific reports · 2026Article
- Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.ESMO open · 2026Article
- Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.British journal of cancer · 2025Article
- Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy.Frontiers in public health · 2025Article
- Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Highly consistency ofHeliyon · 2024Article
- Article
- Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.Molecular biology reports · 2023Review
- Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.Cancer treatment and research communications · 2023Article
- Article
- Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.Current oncology (Toronto, Ont.) · 2021Article
- Review
- Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation.Clinical epidemiology · 2021Article
- Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients.Journal of thoracic disease · 2020Article
- Distribution of pathogenic bacteria in lower respiratory tract infection in lung cancer patients after chemotherapy and analysis of integron resistance genes in respiratory tract isolates of uninfected patients.Journal of thoracic disease · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.